Title:
TREATMENT OF DISORDERS ASSOCIATED WITH LOW BH4 BIOAVAILABILITY
Document Type and Number:
WIPO Patent Application WO/2022/136851
Kind Code:
A9
Abstract:
The present invention relates to the use of a reduced folate, such as 5-MTHF (5- methyltetrahydrofolate), optionally in combination with tetrahydrobiopterin (BH4) or precursors thereof, for preventing or treating disorders associated with a BH4 deficiency, or low BH4 bioavailability. Such disorders primarily include diseases which have vascular endothelial pathology, or effects on amino acid metabolism or neurotransmission, especially pregnancy related disorders such as pre-eclampsia.
Inventors:
CHANNON KEITH (GB)
Application Number:
PCT/GB2021/053382
Publication Date:
July 20, 2023
Filing Date:
December 21, 2021
Export Citation:
Assignee:
UNIV OXFORD INNOVATION LTD (GB)
International Classes:
A61K31/519; A61P9/12; A61P43/00
Attorney, Agent or Firm:
HGF (GB)
Download PDF: